With the global population continuing to grow and the demand for increased food production rising, the agricultural adjuvant ...

Should patients with TNBC who did not receive immunotherapy before surgery get it after, if they have residual disease?

After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival ...

Investigators explored the role of treatment intensification with androgen receptor pathway inhibitors in patients with high-risk localized prostate cancer.

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

A new nasal whooping cough vaccine showed an ability to prevent both infection and transmission of the disease in mice. Current vaccines offer treatment but fail to halt transmission of the bacteria ...

Oleg Gligich, MD, assistant professor at the Columbia University Division of Hematology/Oncology at Mount Sinai Medical ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...